CHC 2018: DR. Jennifer Brown - Relapsed CLL in 2018

CHC 2018: DR. Graeme Fraser - Chronic Lymphocytic Leukemia (CLL)Подробнее

Dr. Jennifer Brown on Gauging Response in CLLПодробнее

Jennifer R. Brown, MD, PhD: The Changing Definition of “High-Risk” CLLПодробнее

Dr. Jennifer Brown Discusses Single Agents in CLLПодробнее

Dr Jennifer Brown on the Role of Genomic Sequencing in CLLПодробнее

Dr. Jennifer Brown on Ibrutinib, Idelalisib, and Other Agents for CLLПодробнее

Jennifer Brown, MD, PhD, on the CLL Sessions to Watch at the SOHO Annual MeetingПодробнее

Dr. Jennifer Brown on Mutations and Targets in CLLПодробнее

Duvelisib in Relapsed/Refractory CLLПодробнее

Dr. Jennifer Brown Discusses Final Stage 2 Results of the CLL11 TrialПодробнее

Dr. Jennifer Brown on CLL Mutations, Pathways, and TargetsПодробнее

Q&A with Jennifer Brown on CLLПодробнее

Dr. Jennifer Brown on FCR and Ibrutinib in CLLПодробнее

Targeted therapies for CLL: new data and unanswered questionsПодробнее

Dr. Jennifer Brown on RESONATE 2 Trial in CLLПодробнее

Dr. Jennifer Brown on the Role of FCR in CLLПодробнее

Dr. Brown Discusses New Drugs on the Horizon in CLLПодробнее

Dr. Brown on the Development of Treatments for CLLПодробнее